XTX Topco Ltd Acquires Shares of 20,889 Definitive Healthcare Corp. (NASDAQ:DH)

XTX Topco Ltd bought a new position in Definitive Healthcare Corp. (NASDAQ:DH) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 20,889 shares of the company’s stock, valued at approximately $93,000.

Several other institutional investors also recently modified their holdings of DH. The Manufacturers Life Insurance Company grew its holdings in shares of Definitive Healthcare by 17.0% during the second quarter. The Manufacturers Life Insurance Company now owns 22,896 shares of the company’s stock valued at $125,000 after buying an additional 3,332 shares during the last quarter. Principal Financial Group Inc. lifted its position in Definitive Healthcare by 10.8% during the second quarter. Principal Financial Group Inc. now owns 39,856 shares of the company’s stock valued at $218,000 after purchasing an additional 3,874 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Definitive Healthcare by 31.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,292 shares of the company’s stock worth $116,000 after purchasing an additional 5,083 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in Definitive Healthcare by 41.1% in the third quarter. Glenmede Trust Co. NA now owns 18,423 shares of the company’s stock worth $82,000 after purchasing an additional 5,362 shares during the last quarter. Finally, Point72 DIFC Ltd raised its stake in Definitive Healthcare by 759.9% during the 3rd quarter. Point72 DIFC Ltd now owns 9,296 shares of the company’s stock valued at $42,000 after buying an additional 8,215 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors.

Definitive Healthcare Price Performance

NASDAQ DH opened at $4.18 on Friday. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. Definitive Healthcare Corp. has a 12 month low of $3.19 and a 12 month high of $10.62. The stock has a market cap of $482.89 million, a price-to-earnings ratio of -1.35, a PEG ratio of 3.29 and a beta of 1.40. The company’s 50 day moving average is $4.41 and its two-hundred day moving average is $4.68.

Insider Transactions at Definitive Healthcare

In other news, insider William Moschella sold 45,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $4.70, for a total value of $211,500.00. Following the completion of the transaction, the insider now owns 433,830 shares of the company’s stock, valued at $2,039,001. This represents a 9.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 14.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DH. Stephens began coverage on Definitive Healthcare in a report on Friday. They issued an “equal weight” rating and a $5.00 price objective for the company. BTIG Research initiated coverage on Definitive Healthcare in a research note on Tuesday, September 17th. They set a “buy” rating and a $7.00 price target for the company. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Definitive Healthcare currently has an average rating of “Hold” and a consensus target price of $5.72.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.